STOCK TITAN
  1. Home
  2. Sec-filings
  3. AQST
  4. [Form 4] Aquestive Therapeutics, Inc. Insider Trading Activity

Aquestive (AQST) director granted 50,500 stock options at $3.99

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aquestive Therapeutics director Julie Krop received a compensation-related stock option grant. She was awarded options to purchase 50,500 shares of Common Stock at an exercise price of $3.99 per share, expiring on June 10, 2036.

All 50,500 underlying shares vest 100% on June 10, 2027, subject to Dr. Krop’s continuous service with Aquestive Therapeutics through that date. After this grant, she holds 50,500 stock options directly, and the filing reports no share sales or open-market purchases.

Positive

  • None.

Negative

  • None.
Insider Krop Julie
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Purchase) 50,500 $0.00 --
Holdings After Transaction: Stock Option (Right to Purchase) — 50,500 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Stock options granted 50,500 options Grant to director Julie Krop
Exercise price $3.99 per share Stock Option (Right to Purchase)
Underlying shares 50,500 shares Common Stock underlying the options
Expiration date June 10, 2036 Option term end date
Vesting date June 10, 2027 100% of underlying shares vest
Options held after grant 50,500 options Total derivative holdings following transaction
Stock Option (Right to Purchase) financial
"security_title: Stock Option (Right to Purchase)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
continuous service financial
"subject to Dr. Krop's continuous service with the Issuer"
vesting date financial
"through the applicable vesting date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Krop Julie
(Last)(First)(Middle)
C/O AQUESTIVE THERAPEUTICS, INC.
30 TECHNOLOGY DRIVE
(Street)
WARREN NEW JERSEY 07059
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Purchase)$3.9906/10/2026A50,50006/10/2027(1)06/10/2036Common Stock50,500$050,500D
Explanation of Responses:
1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Dr. Krop's continuous service with the Issuer from the grant date through the applicable vesting date.
Remarks:
/s/ Thomas Zalewski, as Attorney-In-Fact06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Julie Krop report in her latest Form 4 for Aquestive Therapeutics (AQST)?

Julie Krop reported receiving a new stock option grant. She was awarded options for 50,500 shares of Aquestive Therapeutics Common Stock at a $3.99 exercise price, expiring June 10, 2036, with no share sales disclosed.

How many Aquestive Therapeutics (AQST) options did Julie Krop receive and at what price?

Julie Krop received options for 50,500 shares at $3.99 per share. These stock options give her the right to purchase Aquestive Therapeutics Common Stock at that exercise price until their June 10, 2036 expiration date.

When do Julie Krop’s new Aquestive Therapeutics (AQST) stock options vest?

The options vest in full on June 10, 2027. All 50,500 underlying shares vest 100% on that date, provided Dr. Krop continues serving with Aquestive Therapeutics through the vesting date as specified in the grant terms.

Did Julie Krop buy or sell any Aquestive Therapeutics (AQST) shares in this Form 4?

No open-market buys or sells were reported. The filing only shows a grant of stock options classified as a grant, award, or other acquisition, with 50,500 options reported and no sales or purchases of Common Stock.

What is the term of Julie Krop’s new stock options at Aquestive Therapeutics (AQST)?

The options expire on June 10, 2036. She may exercise the 50,500 stock options at $3.99 per share after vesting and before this expiration date, subject to her continued service and the plan’s standard conditions.